Presented through a grant from Process for PRF, Presidential Sponsor

Biologically, growth factors are always active and are essential for all types of wound healing. However, clinically, the most frequent question is: Are they always active?

The objective of this course is to understand how the growth factors are active and how we can constantly improve the results in clinical use for soft tissue management and bone augmentations.

The evidence is more known today: the growth factors are released by platelets and white cells. They need several conditions and other substances to be really successful. There are also many factors that counteract their activity.

The new protocol A-PRF, Advanced Platelet Rich Fibrin, is the most powerful concept as it combines the fibrin network, the growth factors from the platelets, and the white cell activity for only one goal: getting more rapid and thorough vascularization. APRF is a “blood concentrate” and not a “platelet concentrate.” The A-PRF protocol proposes the better composition for the healing cascade: cytokins with slow release, full natural fibrin, monocytes, granulocytes and plasma proteins, with long-term release of autologus BMP-2.

The i-PRF is proposed with the same concept: platelets, white cells, fibrinogen in liquid form produced without any additive or anticoagulant: it clots after the injection. The goal is to improve the soft tissue biotype without surgery, only by injection.

This course introduces the notion of strict and specific protocols: without specific protocols allowed to each clinical indication, the results should be random. The negative factors that antagonize the PRF successful will be presented in great detail.